Jesper Brandgaard ny formand for LEO Pharmas bestyrelse
LEO Fondet har udpeget Jesper Brandgaard som ny formand for LEO Pharmas bestyrelse. Han afløser Olivier Bohuon, der i maj valgte at forlade formandsposten. Jesper Brandgaard overtager formandsposten den 1. august 2021.
”Det glæder mig meget, at Jesper Brandgaard har sagt ja til at være formand for LEO Pharmas bestyrelse. Jesper kommer med omfattende ekspertise og erfaring fra medicinalindustrien og har skabt markante resultater gennem sine 20 år i Novo Nordisk, heraf 17 år som CFO, hvor han spillede en nøglerolle i virksomhedens globale vækst og succes. Samtidig kommer han med solid erfaring fra bestyrelsesposter i en række både børsnoterede og ikke-børsnoterede virksomheder samt indgående kendskab til den danske fondsejerskabsmodel. Der er ingen tvivl om, at Jespers betydelige erfaring og viden indenfor medicinalindustrien, hans integritet og brede forretningsforståelse vil være et stort aktiv, der kan understøtte LEO Pharmas ambitiøse vækststrategi de kommende år,” siger Lars Olsen, formand for LEO Fondets bestyrelse.
Jesper Brandgaard overtager formandsposten den 1. august 2021.
”LEO Pharma er et unikt selskab med en stærk platform inden for hudsygdomme – og et stort potentiale. Det er et privilegium at blive en del af LEO Pharmas rejse mod globalt lederskab inden for dermatologi, og jeg ser meget frem til at bidrage til realiseringen af LEO Pharmas ambitioner,” siger Jesper Brandgaard.
Jesper Brandgaard har en kandidatgrad i økonomi og revision samt en MBA, begge fra Copenhagen Business School. I 1999 blev han ansat som Senior Vice President for Corporate Finance i Novo Nordisk A/S og blev udnævnt til CFO i 2000. Han forlod Novo Nordisk i 2019 for at forfølge en karriere som professionelt bestyrelsesmedlem. Han er medlem af flere bestyrelser, herunder næstformand for Chr. Hansen Holding, næstformand for William Demant Invest, bestyrelsesmedlem i William Demant Fonden, medlem af Komitéen for god Selskabsledelse og medlem af Vækstpartner Kapitals advisory board.
Kontakter
Signe Krabek, Head of Communication and Public Affairs
Tlf: +45 20 49 68 69
E-mail: signe.krabek@leo-foundation.org
Billeder
Information om LEO Pharma
Om LEO Fondet
LEO Fondet er en af Danmarks største erhvervsdrivende fonde og engageret ejer af medicinalvirksomheden LEO Pharma. Fondet har som primært formål at sikre virksomhedens langsigtede udvikling og succes som en global leder inden for dermatologi, der leverer konkurrencedygtige resultater.
Udover ejerskabet af LEO Pharma uddeler Fondet filantropisk støtte til international forskning i hud og hudsygdomme og arbejder for at gøre Danmark til et globalt fyrtårn inden for hudforskning.
LEO Fondet har en formue på ca. DKK 16 mia. Afkast fra investering af formuen skal sikre evnen til at understøtte LEO Pharmas langsigtede udvikling samt Fondets filantropiske aktiviteter.
Om LEO Pharma
LEO Pharma er en globalt førende virksomhed inden for medicinsk dermatologi. Virksomheden har en robust pipeline og tilbyder en bred vifte af behandlinger og behandlingstyper. LEO Pharma blev dannet i 1908 som Danmarks første medicinalvirksomhed – og med en høj innovationsgrad har man i årtier drevet forskning og udvikling for at kunne tilbyde nye innovative behandlinger til patienter med hudsygdomme. LEO Pharma har hovedsæde i Danmark og har 6.000 ansatte. Virksomhedens behandlinger sælges i 130 lande og hjælper hvert år mere end 93 millioner patienter.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma continues global rollout of Anzupgo® (delgocitinib) cream with submission of New Drug Application in China16.10.2025 15:30:00 CEST | Pressemeddelelse
LEO Pharma is seeking to expand the availability of Anzupgo® (delgocitinib) cream to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA), which has been accepted for review for adult patients with moderate to severe chronic hand eczema. The NDA is supported by results from DELTA China, a phase 3 trial with Anzupgo in Chinese adults with moderate to severe chronic hand eczema (CHE)1 along with the full clinical program of delgocitinib, which includes data from DELTA 1,2 and 3, DELTA Force and DELTA Teen.2-7 The Anzupgo NDA submission demonstrates LEO Pharma's commitment to providing additional treatment options for patients living with skin diseases in China.
LEO Pharma closes deal for Spevigo®1.10.2025 09:00:00 CEST | Pressemeddelelse
Adding Spevigo® is a significant step forward in LEO Pharma’s focused growth strategy, to accelerate and expand patients’ access to treatments for medical dermatological conditions, including generalized pustular psoriasis (GPP), a rare and severe skin condition Spevigo® (spesolimab) is a first-in-class IL-36R antagonist successfully developed and launched by Boehringer Ingelheim and approved globally for the treatment and prevention of GPP flares Spesolimab is also being investigated for the treatment of other IL-36-mediated skin diseases
LEO Pharma Presents Late-Breaking Data at EADV 2025 Showing Week 16 Tralokinumab Response Predicts Long-Term Response in Moderate-to-Severe Atopic Dermatitis19.9.2025 16:00:00 CEST | Pressemeddelelse
Late-breaking data from the ECZTEND trial show that patients with moderate-to-severe atopic dermatitis (AD), who responded to Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) at Week 16, maintained stable, optimal treatment outcomes for up to three years.1 Additional data presented at EADV from the real-world TRACE study further support the long-term use of tralokinumab, with sustained improvements in disease severity, quality of life, sleep, and work productivity observed over 12 months of treatment.2-4 Presented as part of LEO Pharma’s most ambitious scientific program to date at the 2025 EADV Congress, the tralokinumab data reinforce the company’s leadership in medical dermatology and its commitment to advancing innovation across its biologics’ portfolio.
LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)18.9.2025 15:45:00 CEST | Pressemeddelelse
The first late-breaking presentation was the phase 3 trial results for DELTA TEEN, showing delgocitinib cream had superior efficacy compared to cream vehicle and was generally well tolerated in adolescents, aged 12-17, with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 In a second late-breaking presentation, pooled data from five phase 2b and phase 3 trials of delgocitinib cream confirmed a consistent safety profile for the treatment of moderate to severe CHE in adults.2 Fifteen other pieces of delgocitinib cream research formed part of LEO Pharma’s most ambitious scientific program to date at EADV 2025.3-17
LEO Pharma presents two late-breaking abstracts for temtokibart reporting positive Phase 2b efficacy, safety and biomarker results in moderate-to-severe atopic dermatitis at the 2025 EADV Annual Meeting in Paris17.9.2025 16:00:00 CEST | Pressemeddelelse
Results presented at EADV 2025 demonstrated that investigational agent temtokibart met its primary endpoint of percentage change in the Eczema Area and Severity Index (EASI) compared with placebo for the three highest doses (600 mg, 450 mg, and 300 mg).1 Significantly greater improvements in EASI were reported as early as Week 1 for temtokibart 450mg and 300mg, and Week 2 for 600mg, vs placebo; these results were maintained up to Week 32 in 600mg and 300mg arms, despite no treatment after Week 14.1 Safety analyses revealed that temtokibart was well-tolerated with no dose-dependent AEs, a low incidence of conjunctivitis, and no signal for herpes.1
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum